Web16 feb 2024 · PURPOSE For patients with metastatic hormone-sensitive prostate cancer, metastatic burden affects outcome. We examined efficacy and safety from the ARASENS trial for subgroups by disease volume and risk. METHODS Patients with metastatic hormone-sensitive prostate cancer were randomly assigned to darolutamide or placebo … Web3 dic 2024 · Phase III ARASENS trial meets primary endpoint of overall survival for NUBEQA in combination with docetaxel and androgen deprivation therapy (ADT) versus docetaxel and ADT, a standard of care in men with metastatic hormone-sensitive prostate cancer (mHSPC) Bayer plans to present these pivotal data at a forthcoming scientific …
Uromigos Episode 155: ASCO GU 2024 ARASENS Trial Review
Web18 feb 2024 · In ARASENS (NCT02799602), patients with cytologically confirmed metastatic adenocarcinoma of the prostate were eligible for the trial. All participants needed to be candidates for ADT and docetaxel, have an ECOG performance status of 0 or 1, and have adequate organ function. Web25 mar 2024 · So ARASENS was launched to see if it could do the same in men with prostate cancer that has spread. Improved survival at 4 years. In the ARASENS trial, nearly 1,300 participants were randomly assigned to receive darolutamide or a placebo (both taken as a pill, twice a day). dr richard lee allergist new milford ct
OncLive.com on Twitter: "WATCH: Expert oncologist Matthew …
Web3 giu 2024 · What is this summary about? This is a summary of a publication about the ARASENS trial, which was published in the New England Journal of Medicine in February 2024. The trial includes 1,306 men with a type of prostate cancer called metastatic, hormone-sensitive prostate cancer (also called mHSPC). In the trial, researchers wanted … Web22 mar 2024 · Massimo Di Maio. Una serie di documentari dedicati ai Centri oncologici italiani abilitati alla diagnosi e alla gestione del paziente con fusione NTRK. Ogni puntata … Web27 apr 2024 · In the absence of that, how do you incorporate the ARASENS data into your clinical decision-making? Evan Y. Yu, MD: That’s a great question. Obviously, we’re … dr richard lee griffiths